202 related articles for article (PubMed ID: 24858343)
1. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
Ruvolo PP; Ruvolo VR; Jacamo R; Burks JK; Zeng Z; Duvvuri SR; Zhou L; Qiu Y; Coombes KR; Zhang N; Yoo SY; Pan R; Hail N; Konopleva M; Calin G; Kornblau SM; Andreeff M
Biochim Biophys Acta; 2014 Sep; 1843(9):1969-77. PubMed ID: 24858343
[TBL] [Abstract][Full Text] [Related]
2. Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.
Shouse G; de Necochea-Campion R; Mirshahidi S; Liu X; Chen CS
Oncotarget; 2016 Sep; 7(38):61081-61092. PubMed ID: 27531894
[TBL] [Abstract][Full Text] [Related]
3. Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
Ruvolo PP; Qui YH; Coombes KR; Zhang N; Ruvolo VR; Borthakur G; Konopleva M; Andreeff M; Kornblau SM
Leukemia; 2011 Nov; 25(11):1711-7. PubMed ID: 21660042
[TBL] [Abstract][Full Text] [Related]
4. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
Roberts KG; Smith AM; McDougall F; Carpenter H; Horan M; Neviani P; Powell JA; Thomas D; Guthridge MA; Perrotti D; Sim AT; Ashman LK; Verrills NM
Cancer Res; 2010 Jul; 70(13):5438-47. PubMed ID: 20551067
[TBL] [Abstract][Full Text] [Related]
5. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Yang Y; Huang Q; Lu Y; Li X; Huang S
J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
[TBL] [Abstract][Full Text] [Related]
6. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt.
Kuo YC; Huang KY; Yang CH; Yang YS; Lee WY; Chiang CW
J Biol Chem; 2008 Jan; 283(4):1882-92. PubMed ID: 18042541
[TBL] [Abstract][Full Text] [Related]
7. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
Zonta F; Pagano MA; Trentin L; Tibaldi E; Frezzato F; Trimarco V; Facco M; Zagotto G; Pavan V; Ribaudo G; Bordin L; Semenzato G; Brunati AM
Blood; 2015 Jun; 125(24):3747-55. PubMed ID: 25931585
[TBL] [Abstract][Full Text] [Related]
8. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
Chen L; Luo LF; Lu J; Li L; Liu YF; Wang J; Liu H; Song H; Jiang H; Chen SJ; Luo C; Li KK
PLoS One; 2014; 9(7):e103033. PubMed ID: 25050888
[TBL] [Abstract][Full Text] [Related]
9. The B55α regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes.
Kolupaeva V; Daempfling L; Basilico C
Mol Cell Biol; 2013 Aug; 33(15):2865-78. PubMed ID: 23716589
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-494 Activation Suppresses Bone Marrow Stromal Cell-Mediated Drug Resistance in Acute Myeloid Leukemia Cells.
Tian C; Zheng G; Zhuang H; Li X; Hu D; Zhu L; Wang T; You MJ; Zhang Y
J Cell Physiol; 2017 Jun; 232(6):1387-1395. PubMed ID: 27696394
[TBL] [Abstract][Full Text] [Related]
11. c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia.
Su R; Gong JN; Chen MT; Song L; Shen C; Zhang XH; Yin XL; Ning HM; Liu B; Wang F; Ma YN; Zhao HL; Yu J; Zhang JW
Oncotarget; 2016 Nov; 7(47):77430-77443. PubMed ID: 27764807
[TBL] [Abstract][Full Text] [Related]
12. The Interplay between PP2A and microRNAs in Leukemia.
Ruvolo PP
Front Oncol; 2015; 5():43. PubMed ID: 25750899
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
[TBL] [Abstract][Full Text] [Related]
14. Protein phosphatase 2A is regulated by protein kinase Cα (PKCα)-dependent phosphorylation of its targeting subunit B56α at Ser41.
Kirchhefer U; Heinick A; König S; Kristensen T; Müller FU; Seidl MD; Boknik P
J Biol Chem; 2014 Jan; 289(1):163-76. PubMed ID: 24225947
[TBL] [Abstract][Full Text] [Related]
15. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
16. Tumor-suppressive MEG3 induces microRNA-493-5p expression to reduce arabinocytosine chemoresistance of acute myeloid leukemia cells by downregulating the METTL3/MYC axis.
Wang A; Chen Y; Shi L; Li M; Li L; Wang S; Wang C
J Transl Med; 2022 Jun; 20(1):288. PubMed ID: 35761379
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA UCA1 modulates cell proliferation and apoptosis by regulating miR-296-3p/Myc axis in acute myeloid leukemia.
Li J; Wang M; Chen X
Cell Cycle; 2020 Jun; 19(12):1454-1465. PubMed ID: 32286143
[TBL] [Abstract][Full Text] [Related]
18. Silencing long non-coding RNA XIST suppresses drug resistance in acute myeloid leukemia through down-regulation of MYC by elevating microRNA-29a expression.
Wang C; Li L; Li M; Wang W; Liu Y; Wang S
Mol Med; 2020 Nov; 26(1):114. PubMed ID: 33228517
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.
De Luca L; Trino S; Laurenzana I; Tagliaferri D; Falco G; Grieco V; Bianchino G; Nozza F; Campia V; D'Alessio F; La Rocca F; Caivano A; Villani O; Cilloni D; Musto P; Del Vecchio L
Cell Death Dis; 2017 Jun; 8(6):e2849. PubMed ID: 28569789
[TBL] [Abstract][Full Text] [Related]
20. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
